CSF3 and non-Hodgkin lymphoma: Among all other patients who did not receive G-CSF prophylaxis in cycle 1 (n = 666/749; 88.9%), FN incidence was 5.3% (range: 3.4% [colorectal cancer and NHL, each] to 7.5% [breast cancer]) during cycle 1 and 14.3% (range: 12.3% [colorectal cancer] to 24.1% [NHL]) during the course.